90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
Status:
Withdrawn
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study is for patients with neuroblastoma or a neuroendocrine tumor who have not been
able to have standard therapy or have failed the first-line therapy. The purpose of this
study is to assess the safety and effectiveness of the combination of retinoic acid and
Onalta (Y-90-DOTA-tyr3-Octreotide) in treating neuroblastoma and neuroendocrine tumors.